nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial
|
Sandmaier, Brenda M |
|
|
6 |
8 |
p. e409-e418 |
artikel |
2 |
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
|
Davids, Matthew S |
|
|
6 |
8 |
p. e419-e428 |
artikel |
3 |
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
|
Morschhauser, Franck |
|
|
6 |
8 |
p. e429-e437 |
artikel |
4 |
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs
|
Wendtner, Clemens-Martin |
|
|
6 |
8 |
p. e389-e390 |
artikel |
5 |
Sickle cell disease: a new era
|
Simpson, Shmona |
|
|
6 |
8 |
p. e393-e394 |
artikel |
6 |
Sirolimus-based graft-versus-host disease prophylaxis
|
Ruggeri, Annalisa |
|
|
6 |
8 |
p. e387-e388 |
artikel |
7 |
The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia
|
Andrews, Claire N |
|
|
6 |
8 |
p. e385-e386 |
artikel |
8 |
24th European Hematology Association Congress
|
Smith, Lan-Lan |
|
|
6 |
8 |
p. e396-e397 |
artikel |
9 |
The value of affordable care
|
The Lancet Haematology, |
|
|
6 |
8 |
p. e384 |
artikel |
10 |
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
|
Shih, Ya-Chen Tina |
|
|
6 |
8 |
p. e398-e408 |
artikel |
11 |
War in the Blood: experiencing CAR-T cell therapy
|
Burki, Talha K |
|
|
6 |
8 |
p. e395 |
artikel |
12 |
Will GALEN become more RELEVANT?
|
von Keudell, Gottfried |
|
|
6 |
8 |
p. e391-e392 |
artikel |